https://la-newswire.com/wp-content/uploads/2021/11/18790.jpg
295
80
Merci
Merci
https://la-newswire.com/wp-content/uploads/2021/09/Merci-96x96.jpg
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 20, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A…